US 7,589,078 B2
Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections
Yung-chi Cheng, Woodbridge, Conn. (US); Hiromichi Tanaka, Yokohama (Japan); and Masanori Baba, Kagoshima (Japan)
Assigned to Yale University, New Haven, Conn. (US)
Filed on Feb. 18, 2004, as Appl. No. 10/781,305.
Claims priority of provisional application 60/448554, filed on Feb. 19, 2003.
Prior Publication US 2004/0167096 A1, Aug. 26, 2004
Int. Cl. A01N 43/04 (2006.01); A61K 31/70 (2006.01); C07H 19/00 (2006.01)
U.S. Cl. 514—49  [514/50; 514/51; 536/28.2; 536/28.4; 536/28.5; 536/28.53; 536/28.54; 536/28.55] 36 Claims
 
1. A compound according to the formula:

OG Complex Work Unit Drawing
Wherein B is

OG Complex Work Unit Drawing
R is H, F, Cl, Br, I, C1-C4 alkyl, —C≡N, —C≡C—Ra,

OG Complex Work Unit Drawing
X is H, C1-C4 alkyl, F, Cl, Br or I;
R1 is H, an acyl group, a C1-C20 alkyl or an ether group;
R2 is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a

OG Complex Work Unit Drawing
group;
Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate,
carbonate or urethane group with the adjacent moiety;
R8 is H or a C1-C20 alkyl or ether group;
R3 is a C3 or C4 alkyl group, or a —(CH2)n—C≡C—Ra group;
R3a and R3b are each independently H, F, Cl, Br and I;
Ra is H, F, Cl, Br, I, or —C1-C4 alkyl;
Y is H, F, Cl, Br, I or —C1-C4 alkyl;
k is 0, 1 or 2; and
n is 0, 1, 2, 3, 4 or 5;
or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof.